{"ticker": {"uuid": "bfc27627-a8bd-4d3b-8a91-cd08717e9c47", "symbol": "OKYO", "name": "OKYO Pharma Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Cuts Target Price to $5", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPeHo3ZHc1NVRzZXY3VW9NOEkxdzZ2bGtyOGVfejhuWG1UZ0JoczBMWERTbk5PWGtKTnZsZm9fald6VlFQT1VSLXUxU1RHNHo3M3dlNXZhNy02cF8yQzgxbHlyUDdVLXJINVNGcEw3Qlo3dDdBRXNBQVFwNjVJZmNUX2wtUGVuT2RycFFlZjI0dnhhbWlnTjRJcWRUYWs4dnJ3THhkZGVvNA?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T09:38:16+00:00", "published_display": "14 Jul 2026 09:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright cuts OKYO Pharma stock price target to $5 on share count", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRzdSUVh6ZXFmUXM3bVNQSC1GOGtTNUVIOFNsTnlMeEpvWkJsSTB1Q2hOT0QwaTVHRm45cUNGN21teHNKRkQzRzg2WFQ2bmFZTUNzNVFVQ01PR1RuRmpMdF8tMFR6WEhEYkthLWU4S0RPWW5kaUN4dU1lNHp5TXNiemNuczFJRlFub3FUTFNIZTZrZHVkYUNzSWZnMm5OM1V0N2xHR3BCdklDVDYyUVlnZ0ZqdEFreFdQc21kbFFmYlQ1RktrSWZ3Ng?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T12:08:14+00:00", "published_display": "13 Jul 2026 12:08", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma advances toward Phase 3 FDA trial - ICYMI", "summary": "", "url": "https://finance.yahoo.com/m/a3daf01c-60cb-3d72-aebb-663a8c7bfa0a/okyo-pharma-advances-toward.html", "source_name": "Proactive", "published_at": "2026-07-11T14:00:00+00:00", "published_display": "11 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (Nasdaq:OKYO) - Stock Analysis", "summary": "OKYO Pharma, a clinical-stage biopharmaceutical company, is advancing its lead candidate, urcosimod, for neuropathic corneal pain (NCP) into a global Phase 3 pivotal trial following positive FDA feedback. Despite this progress, the company faces significant financial risks includ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-okyo/okyo-pharma", "source_name": "Simply Wall Street", "published_at": "2026-07-09T20:09:32", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain", "summary": "OKYO Pharma has received positive feedback from the U.S. FDA, validating its strategy to advance urcosimod into a global Phase 3 trial for neuropathic corneal pain. The FDA supported a single-dose Phase 3 study design, potentially allowing for a single-trial registration pathway.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/OKYO-Q/pressreleases/3201868/okyo-pharma-secures-fda-backing-to-advance-urcosimod-into-global-phase-3-trial-for-neuropathic-corneal-pain/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T06:30:00", "published_display": "09 Jul 2026 06:30", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain", "summary": "", "url": "https://finance.yahoo.com/m/5367618f-7f9e-355a-9cc4-4ed14d897362/okyo-pharma-reports-fda.html", "source_name": "Proactive", "published_at": "2026-07-08T12:33:00+00:00", "published_display": "08 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxQRGFZOTlWU183ZFVjNV9pZUdPemxjdmFJaG80N2NaWUgwMi1VQ1NRS25lTEdVYk8zV1VNS0F5WWVYbVdCQkhIWGFvSUhsMXdSRlRBbFVhdS1vWUQ4X0RabHliQlpMSVY1Y3RBSHNpY2hST0pMa29VZ0JnMncwa3RvQjlKbHJmWVBMMGdQV2dFT2dueURoV1hDVGZ4Rk03eEszcm1vTXR1Y19vTFphM2h1T3hYUjBDSThCTHB6WF9mLU1DMGs0aUVLNElMTFJJMkJlSlg2SUo3eU9GN2Vub1JKRDBiSFcyUHIzLVBmcHlMZmR4MzM5eU9CNmM0UkZla2Y5N3lTYTBXc0h5UkZTS1VBZXZtOUI1bk9MN1Fv?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T11:30:00+00:00", "published_display": "08 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod  to Treat Neuropathic Corneal Pain", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/okyo-pharma-receives-apos-positive-112854145.html", "source_name": "MT Newswires", "published_at": "2026-07-08T11:28:54+00:00", "published_display": "08 Jul 2026 11:28", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma advances urcosimod into global Phas...", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOSi16aWM0MXlWN1JFd0JJQkg3QzQxTDdWX1Z0ZjhTSlNBdjFTZG9xRHVIeG1RZVdVSDh5YUxlWk5NMjBiTzJqQXlkdFpaaTFKWE52VjJJSVB0Y1AzMUlwWWdtMGpXYkFqLW9YRVdjTWhtMmYwZXFMN2RmYWlTeEI3c2dJUFBsVEkzVWFOVjJaaWtVYWVZbGxpTE1BTFU3TEs2ZlRiT0ZpZnYwRGgw?oc=5", "source_name": "Pluang", "published_at": "2026-07-08T11:21:07+00:00", "published_display": "08 Jul 2026 11:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial", "summary": "OKYO Pharma Limited (NASDAQ:OKYO) announced that it received FDA feedback on its clinical development program for urcosimod, a treatment for neuropathic corneal pain, supporting the advancement into a global Phase 3 pivotal trial. The company's shares rose nearly 17% over the pas", "url": "https://www.investing.com/news/company-news/okyo-pharma-receives-fda-feedback-on-phase-3-neuropathic-pain-trial-93CH-4781282", "source_name": "Investing.com", "published_at": "2026-07-08T12:09:41", "published_display": "08 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study", "summary": "OKYO Pharma (Nasdaq: OKYO) announced positive feedback from the FDA Type D meeting, enabling the advancement of urcosimod into a global Phase 3 pivotal trial called NEPTUNE for neuropathic corneal pain (NCP). The FDA's alignment on a single-dose study design and potential single-", "url": "https://www.stocktitan.net/news/OKYO/okyo-pharma-reports-positive-feedback-from-fda-type-d-meeting-and-rrk1x8np72yq.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:09:41", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial", "summary": "OKYO Pharma received positive FDA feedback on its lead drug candidate, urcosimod, for neuropathic corneal pain (NCP), validating its clinical development path. The FDA aligned with a single-dose global Phase 3 pivotal trial design (NEPTUNE) and acknowledged a potential single-tri", "url": "https://www.stocktitan.net/sec-filings/OKYO/6-k-okyo-pharma-ltd-current-report-foreign-issuer-1964de07ca86.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:09:41", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain", "summary": "OKYO Pharma announced positive feedback from its FDA Type D meeting, validating its regulatory and clinical path for urcosimod and accelerating its advancement into a global Phase 3 pivotal trial for Neuropathic Corneal Pain (NCP). The FDA's input clarifies the company's strategy", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323947/0/en/okyo-pharma-reports-positive-feedback-from-fda-type-d-meeting-and-accelerates-urcosimod-into-global-phase-3-pivotal-trial-for-neuropathic-corneal-pain.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:09:41", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium", "summary": "OKYO Pharma announced its participation in the Piper Sandler Virtual Ophthalmology Symposium on Thursday, July 9, 2026. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli MD, PhD will present, discussing the company's clinical-stage biopharmaceutical developments for", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323040/0/en/okyo-pharma-to-participate-in-a-fireside-chat-at-piper-sandler-2026-virtual-ophthalmology-symposium.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T07:09:32", "published_display": "08 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain", "summary": "", "url": "https://finance.yahoo.com/video/okyo-pharma-clears-key-fda-151808144.html", "source_name": "Proactive", "published_at": "2026-07-07T15:18:08+00:00", "published_display": "07 Jul 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma CEO to speak at Piper Sandler virtual eye event July 9", "summary": "OKYO Pharma (Nasdaq: OKYO) will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026, at 8:30 AM ET. CEO Robert J. Dempsey and CMO Flavio Mantelli will discuss neuropathic corneal pain and anterior segment eye diseases, a focus ", "url": "https://www.stocktitan.net/news/OKYO/okyo-pharma-to-participate-in-a-fireside-chat-at-piper-sandler-2026-j88r9rphnahv.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:41:03", "published_display": "07 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) to join Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat", "summary": "OKYO Pharma (Nasdaq: OKYO) announced its participation in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026, at 8:30 AM ET. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli will discuss the company's progress, including the s", "url": "https://www.stocktitan.net/sec-filings/OKYO/6-k-okyo-pharma-ltd-current-report-foreign-issuer-c09cdb69d86e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:41:03", "published_display": "07 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) Edges Higher as Biotech Stock Tests Key Resistance Near $1.67 - Channel Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOQmlkTzVRcTlZV2R5bmstcVNrRTBfMkFZX2hxMldlSk9EVHp6TlJZc0FPVjZfTC1JZDh2TERBM0dkT1BBUmlzcFQzRGpVNGw5M1lwSzJ2VnladEtYaDNLLVNGbFF0OE1DcU42NWhyY0ZFb1lXdDhpVWNySzdIZWRDTkg0X0k5M21QZ1dHNm5hQXNzbENQUTlaLXdTdGJWX0xfaS1uVFFtSl9SUWc1ZUNhTGpWaWJXcDA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Ltd (OKYO) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9Cd2l4M2N3bkhRb0NOZkpOdnU3ZEw5RFo0TDlQMTBnS1hwUmEyYjZNdnZ1UWlkdllPWnBYT05CX1lWOF90aHhwUGlfVUI3aWI4Y1c0ZzhyMjVheFJ1U3NUb0lRcDdCbEFseE9nam83NGo?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T18:33:11+00:00", "published_display": "18 Jun 2026 18:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3", "summary": "OKYO Pharma Ltd's Chief Medical Officer, Flavio Mantelli, has filed a Form 3 disclosing his holdings of company share options. The filing indicates four option positions, each covering 187,500 underlying shares of common stock with an exercise price of $1.96 per share and an expi", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-3-okyo-pharma-ltd-initial-statement-of-beneficial-ownership-e3ce5b9cca6c.html", "source_name": "Stock Titan", "published_at": "2026-06-17T22:39:13", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners", "summary": "OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock through a grant or award. The shares, valued at $1.72 each, are held via Panetta Partners Limited. This transaction increases Cerrone's indirect holdings ", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-4-okyo-pharma-ltd-insider-trading-activity-a3616b34e7fa.html", "source_name": "Stock Titan", "published_at": "2026-06-11T09:09:36", "published_display": "11 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85", "summary": "OKYO Pharma Ltd.'s Chief Financial Officer, Keeren Rameshchandra Shah, was granted options for 40,000 common shares at an exercise price of $1.85 per share. These compensation-related options become exercisable on June 8, 2027, and expire on June 8, 2036. Following this grant, Sh", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-4-okyo-pharma-ltd-insider-trading-activity-653b0a575bec.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:56", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) director awarded options on 3,500 common shares", "summary": "OKYO Pharma director Bernard Denoyer was granted options for 3,500 common shares with an exercise price of $1.85 per share, expiring on June 8, 2036. This compensation-related award increases his total option holdings to 35,190 shares. The options vest 25% annually over four year", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-4-okyo-pharma-ltd-insider-trading-activity-cea2c0537eca.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:56", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO)", "summary": "This article provides an in-depth financial overview of OKYO Pharma Ltd. (NASDAQ:OKYO), detailing its current stock price of $1.68, recent performance trends, and key statistics like market capitalization and EPS. It also includes technical analysis ratings, analyst forecasts wit", "url": "https://www.chartmill.com/stock/quote/OKYO/profile", "source_name": "ChartMill", "published_at": "2026-05-29T16:10:43", "published_display": "29 May 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma expands scientific advisory board with cornea expert - ICYMI", "summary": "OKYO Pharma recently appointed Dr. Marta Sacchetti to its scientific advisory board to strengthen its clinical programs for neuropathic corneal pain. The company's lead candidate, Urcosimod, is a non-opioid eye drop designed to alleviate pain and inflammation for this debilitatin", "url": "https://ca.finance.yahoo.com/news/okyo-pharma-expands-scientific-advisory-120000504.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-05-24T00:09:52", "published_display": "24 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Ltd (OKYO) CFO details equity and option positions", "summary": "OKYO Pharma Ltd's CFO, Keeren Rameshchandra Shah, has disclosed his existing equity and option holdings in the company through a Form 3 SEC filing. He directly holds 16,667 shares of common stock. The filing also details numerous option awards, including grants for 31,250 shares ", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-3-okyo-pharma-ltd-initial-statement-of-beneficial-ownership-2c9960e0d26d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:09:27", "published_display": "22 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Okyo Pharma Appoints Marta Sacchetti, MD, Ph.D., to Scientific Advisory Board", "summary": "Okyo Pharma Limited (Nasdaq: OKYO) has expanded its scientific advisory board by appointing Marta Sacchetti, MD, PhD, an associate professor of ophthalmology at Link University in Rome. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases and ocular surface diseases w", "url": "https://www.visionmonday.com/business/article/okyo-pharma-appoints-marta-sacchetti-md-phd-to-scientific-advisory-board/", "source_name": "VisionMonday.com", "published_at": "2026-05-20T12:15:00", "published_display": "20 May 2026 12:15", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes OKYO Pharma (OKYO) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOLVJ0SlJUelVjZTB1UXNoMTNoTG5tWklEUnBNSTFwMlB5b1lxNWtST2FMb2xFTzd1SE1weHJCODJMWkZCQlpFRFVJMWxtMUN3S2YwUW00WGhLV3JCUXFMZmNNMnlfYkpPRmotX1FtZzNEUTBveXo1MEFlSzlHUTdTWWtKRzQ5c1FTVXBaSEd5ZFd0amJqelE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment", "summary": "OKYO Pharma has appointed Dr. Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing the company's expertise in ophthalmic programs. Dr. Sacchetti brings extensive experience in neuro-inflammatory corneal diseases, aligning with OKYO Pharma's focus on unmet needs i", "url": "https://www.proactiveinvestors.ca/companies/news/1092546/okyo-pharma-strengthens-scientific-advisory-board-with-marta-sacchetti-appointment.html?region=ca", "source_name": "Proactive financial news", "published_at": "2026-05-19T14:40:24", "published_display": "19 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma appoints Marta Sacchetti to advisory board By Investing.com", "summary": "OKYO Pharma has appointed Marta Sacchetti, MD, PhD, to its Scientific Advisory Board. Dr. Sacchetti is an Associate Professor of Ophthalmology at Link University in Rome and previously served as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Domp\u00e9 Farmaceut", "url": "https://ca.investing.com/news/stock-market-news/okyo-pharma-appoints-marta-sacchetti-to-advisory-board-93CH-4647966", "source_name": "Investing.com Canada", "published_at": "2026-05-19T11:39:34", "published_display": "19 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD", "summary": "OKYO Pharma Limited has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti, an international expert in ocular inflammatory and degenerative diseases. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases will be crucial for the company's", "url": "https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/okyo-expands-scientific-advisory-board-with-the-appointment-of-international-expert-marta-sacchetti-md-phd/2347017/amp", "source_name": "The Manila Times", "published_at": "2026-05-19T10:39:34", "published_display": "19 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) deepens NCP program with new advisory board expert", "summary": "OKYO Pharma announced the expansion of its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti, an expert in corneal and ocular surface diseases, to bolster its neuropathic corneal pain (NCP) program. The company is developing Urcosimod, an investigational drug ", "url": "https://www.stocktitan.net/sec-filings/OKYO/6-k-okyo-pharma-ltd-current-report-foreign-issuer-e9636def7009.html", "source_name": "Stock Titan", "published_at": "2026-05-19T10:39:34", "published_display": "19 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board", "summary": "OKYO Pharma Ltd (NASDAQ:OKYO) has appointed Dr. Marta Sacchetti, an ophthalmology specialist, to its Scientific Advisory Board. This addition aims to strengthen the company's clinical programs in neuropathic corneal pain and inflammatory eye diseases, leveraging Dr. Sacchetti's e", "url": "https://www.proactiveinvestors.com/companies/news/1092537/okyo-pharma-adds-ophthalmology-specialist-marta-sacchetti-to-scientific-advisory-board-1092537.html", "source_name": "Proactive financial news", "published_at": "2026-05-19T09:58:00", "published_display": "19 May 2026 09:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May", "summary": "OKYO Pharma Limited's CEO, Robert J. Dempsey, and CSO, Raj Patil, PhD, will present at upcoming scientific conferences in May. Dempsey will speak at Eyecelerator on addressing unmet needs in corneal and anterior segment diseases, while Patil will present at the ARVO Annual Meetin", "url": "https://sg.finance.yahoo.com/news/okyo-ceo-cso-present-leadership-110000120.html", "source_name": "Market source", "published_at": "2026-04-30T03:09:34", "published_display": "30 Apr 2026 03:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April", "summary": "OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) experienced a significant 31.9% increase in short interest in April, reaching 272,194 shares. This represents approximately 1.1% of the company's shares sold short, with a days-to-cover ratio of 2.5 days. The company's stock is curr", "url": "https://www.marketbeat.com/instant-alerts/okyo-pharma-limited-sponsored-adr-nasdaqokyo-short-interest-up-319-in-april-2026-04-29/", "source_name": "MarketBeat", "published_at": "2026-04-30T02:10:05", "published_display": "30 Apr 2026 02:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "OKYO Pharma taps Leerink to raise cash for eye pain treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdXdEbWtMb2dMUXJKbUJoMUZKTllGNl9IRC1INWs3VTluM1VsbmdteGtaYzNCdksxeTgtM0VwNXJtTlVmaTZ2amV6bGgwQ1BJRklIaHVLTy1WdWw2VnlBMC11ZjBaTEliRlIxRjY2aW1YYnlCUGNPc3VMeHpMNmVYRlRuWnk2WHZVMC1LYnJYM0xzeVF1WGZtWFZvR09ZWk44dHNKc1JkUHQySXRWa1pfeFpBSjRZVnBPQ3VLcQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Doctor behind $1B rare-disease eye drug joins OKYO Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTVlpYjZkUkVFZkFsUDBxc19Jc1ZkZ3plcmVCRjNfRmczT09YNFpMd0xzZUpGdEg0TVhjYm1vXy1RXzlydkhWOFBtZkJGNXdvdXRyUHlnU1EyUkw3Z1lUOTRCaGY1MEJhVDZlWnJwVnRWLTNEVHdGNDBYR2pWZERGUjZXQkNXa2QwN3J5WGc2X245N3NScUIyWENfb05jYmYxdU9oTzZaM1Rua2xna1d3UGtuLW9rQ2dmWm9iM1pHOW4?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Stock Price and Chart \u2014 NASDAQ:OKYO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBCNUVkcEhQVThLS0padUZUenhWbVhtMjlzcExjR1lmUVVYX2c0WnVmQ0xhT1BqX2FTUnM0Sk44Mkt0RndyZjZnWEdWck5oaG0wSmFUeEV0U084R094?oc=5", "source_name": "TradingView", "published_at": "2025-03-31T07:00:00+00:00", "published_display": "31 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Cuts Target Price to $5", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPeHo3ZHc1NVRzZXY3VW9NOEkxdzZ2bGtyOGVfejhuWG1UZ0JoczBMWERTbk5PWGtKTnZsZm9fald6VlFQT1VSLXUxU1RHNHo3M3dlNXZhNy02cF8yQzgxbHlyUDdVLXJINVNGcEw3Qlo3dDdBRXNBQVFwNjVJZmNUX2wtUGVuT2RycFFlZjI0dnhhbWlnTjRJcWRUYWs4dnJ3THhkZGVvNA?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T09:38:16+00:00", "published_display": "14 Jul 2026 09:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts OKYO Pharma stock price target to $5 on share count", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRzdSUVh6ZXFmUXM3bVNQSC1GOGtTNUVIOFNsTnlMeEpvWkJsSTB1Q2hOT0QwaTVHRm45cUNGN21teHNKRkQzRzg2WFQ2bmFZTUNzNVFVQ01PR1RuRmpMdF8tMFR6WEhEYkthLWU4S0RPWW5kaUN4dU1lNHp5TXNiemNuczFJRlFub3FUTFNIZTZrZHVkYUNzSWZnMm5OM1V0N2xHR3BCdklDVDYyUVlnZ0ZqdEFreFdQc21kbFFmYlQ1RktrSWZ3Ng?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T12:08:14+00:00", "published_display": "13 Jul 2026 12:08", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma advances toward Phase 3 FDA trial - ICYMI", "summary": "", "url": "https://finance.yahoo.com/m/a3daf01c-60cb-3d72-aebb-663a8c7bfa0a/okyo-pharma-advances-toward.html", "source_name": "Proactive", "published_at": "2026-07-11T14:00:00+00:00", "published_display": "11 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (Nasdaq:OKYO) - Stock Analysis", "summary": "OKYO Pharma, a clinical-stage biopharmaceutical company, is advancing its lead candidate, urcosimod, for neuropathic corneal pain (NCP) into a global Phase 3 pivotal trial following positive FDA feedback. Despite this progress, the company faces significant financial risks includ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-okyo/okyo-pharma", "source_name": "Simply Wall Street", "published_at": "2026-07-09T20:09:32", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain", "summary": "OKYO Pharma has received positive feedback from the U.S. FDA, validating its strategy to advance urcosimod into a global Phase 3 trial for neuropathic corneal pain. The FDA supported a single-dose Phase 3 study design, potentially allowing for a single-trial registration pathway.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/OKYO-Q/pressreleases/3201868/okyo-pharma-secures-fda-backing-to-advance-urcosimod-into-global-phase-3-trial-for-neuropathic-corneal-pain/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T06:30:00", "published_display": "09 Jul 2026 06:30", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain", "summary": "", "url": "https://finance.yahoo.com/m/5367618f-7f9e-355a-9cc4-4ed14d897362/okyo-pharma-reports-fda.html", "source_name": "Proactive", "published_at": "2026-07-08T12:33:00+00:00", "published_display": "08 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxQRGFZOTlWU183ZFVjNV9pZUdPemxjdmFJaG80N2NaWUgwMi1VQ1NRS25lTEdVYk8zV1VNS0F5WWVYbVdCQkhIWGFvSUhsMXdSRlRBbFVhdS1vWUQ4X0RabHliQlpMSVY1Y3RBSHNpY2hST0pMa29VZ0JnMncwa3RvQjlKbHJmWVBMMGdQV2dFT2dueURoV1hDVGZ4Rk03eEszcm1vTXR1Y19vTFphM2h1T3hYUjBDSThCTHB6WF9mLU1DMGs0aUVLNElMTFJJMkJlSlg2SUo3eU9GN2Vub1JKRDBiSFcyUHIzLVBmcHlMZmR4MzM5eU9CNmM0UkZla2Y5N3lTYTBXc0h5UkZTS1VBZXZtOUI1bk9MN1Fv?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T11:30:00+00:00", "published_display": "08 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod  to Treat Neuropathic Corneal Pain", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/okyo-pharma-receives-apos-positive-112854145.html", "source_name": "MT Newswires", "published_at": "2026-07-08T11:28:54+00:00", "published_display": "08 Jul 2026 11:28", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma advances urcosimod into global Phas...", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOSi16aWM0MXlWN1JFd0JJQkg3QzQxTDdWX1Z0ZjhTSlNBdjFTZG9xRHVIeG1RZVdVSDh5YUxlWk5NMjBiTzJqQXlkdFpaaTFKWE52VjJJSVB0Y1AzMUlwWWdtMGpXYkFqLW9YRVdjTWhtMmYwZXFMN2RmYWlTeEI3c2dJUFBsVEkzVWFOVjJaaWtVYWVZbGxpTE1BTFU3TEs2ZlRiT0ZpZnYwRGgw?oc=5", "source_name": "Pluang", "published_at": "2026-07-08T11:21:07+00:00", "published_display": "08 Jul 2026 11:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial", "summary": "OKYO Pharma Limited (NASDAQ:OKYO) announced that it received FDA feedback on its clinical development program for urcosimod, a treatment for neuropathic corneal pain, supporting the advancement into a global Phase 3 pivotal trial. The company's shares rose nearly 17% over the pas", "url": "https://www.investing.com/news/company-news/okyo-pharma-receives-fda-feedback-on-phase-3-neuropathic-pain-trial-93CH-4781282", "source_name": "Investing.com", "published_at": "2026-07-08T12:09:41", "published_display": "08 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study", "summary": "OKYO Pharma (Nasdaq: OKYO) announced positive feedback from the FDA Type D meeting, enabling the advancement of urcosimod into a global Phase 3 pivotal trial called NEPTUNE for neuropathic corneal pain (NCP). The FDA's alignment on a single-dose study design and potential single-", "url": "https://www.stocktitan.net/news/OKYO/okyo-pharma-reports-positive-feedback-from-fda-type-d-meeting-and-rrk1x8np72yq.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:09:41", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial", "summary": "OKYO Pharma received positive FDA feedback on its lead drug candidate, urcosimod, for neuropathic corneal pain (NCP), validating its clinical development path. The FDA aligned with a single-dose global Phase 3 pivotal trial design (NEPTUNE) and acknowledged a potential single-tri", "url": "https://www.stocktitan.net/sec-filings/OKYO/6-k-okyo-pharma-ltd-current-report-foreign-issuer-1964de07ca86.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:09:41", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain", "summary": "OKYO Pharma announced positive feedback from its FDA Type D meeting, validating its regulatory and clinical path for urcosimod and accelerating its advancement into a global Phase 3 pivotal trial for Neuropathic Corneal Pain (NCP). The FDA's input clarifies the company's strategy", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323947/0/en/okyo-pharma-reports-positive-feedback-from-fda-type-d-meeting-and-accelerates-urcosimod-into-global-phase-3-pivotal-trial-for-neuropathic-corneal-pain.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:09:41", "published_display": "08 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium", "summary": "OKYO Pharma announced its participation in the Piper Sandler Virtual Ophthalmology Symposium on Thursday, July 9, 2026. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli MD, PhD will present, discussing the company's clinical-stage biopharmaceutical developments for", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323040/0/en/okyo-pharma-to-participate-in-a-fireside-chat-at-piper-sandler-2026-virtual-ophthalmology-symposium.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T07:09:32", "published_display": "08 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain", "summary": "", "url": "https://finance.yahoo.com/video/okyo-pharma-clears-key-fda-151808144.html", "source_name": "Proactive", "published_at": "2026-07-07T15:18:08+00:00", "published_display": "07 Jul 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma CEO to speak at Piper Sandler virtual eye event July 9", "summary": "OKYO Pharma (Nasdaq: OKYO) will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026, at 8:30 AM ET. CEO Robert J. Dempsey and CMO Flavio Mantelli will discuss neuropathic corneal pain and anterior segment eye diseases, a focus ", "url": "https://www.stocktitan.net/news/OKYO/okyo-pharma-to-participate-in-a-fireside-chat-at-piper-sandler-2026-j88r9rphnahv.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:41:03", "published_display": "07 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) to join Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat", "summary": "OKYO Pharma (Nasdaq: OKYO) announced its participation in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026, at 8:30 AM ET. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli will discuss the company's progress, including the s", "url": "https://www.stocktitan.net/sec-filings/OKYO/6-k-okyo-pharma-ltd-current-report-foreign-issuer-c09cdb69d86e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:41:03", "published_display": "07 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) Edges Higher as Biotech Stock Tests Key Resistance Near $1.67 - Channel Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOQmlkTzVRcTlZV2R5bmstcVNrRTBfMkFZX2hxMldlSk9EVHp6TlJZc0FPVjZfTC1JZDh2TERBM0dkT1BBUmlzcFQzRGpVNGw5M1lwSzJ2VnladEtYaDNLLVNGbFF0OE1DcU42NWhyY0ZFb1lXdDhpVWNySzdIZWRDTkg0X0k5M21QZ1dHNm5hQXNzbENQUTlaLXdTdGJWX0xfaS1uVFFtSl9SUWc1ZUNhTGpWaWJXcDA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Ltd (OKYO) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9Cd2l4M2N3bkhRb0NOZkpOdnU3ZEw5RFo0TDlQMTBnS1hwUmEyYjZNdnZ1UWlkdllPWnBYT05CX1lWOF90aHhwUGlfVUI3aWI4Y1c0ZzhyMjVheFJ1U3NUb0lRcDdCbEFseE9nam83NGo?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T18:33:11+00:00", "published_display": "18 Jun 2026 18:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3", "summary": "OKYO Pharma Ltd's Chief Medical Officer, Flavio Mantelli, has filed a Form 3 disclosing his holdings of company share options. The filing indicates four option positions, each covering 187,500 underlying shares of common stock with an exercise price of $1.96 per share and an expi", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-3-okyo-pharma-ltd-initial-statement-of-beneficial-ownership-e3ce5b9cca6c.html", "source_name": "Stock Titan", "published_at": "2026-06-17T22:39:13", "published_display": "17 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners", "summary": "OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock through a grant or award. The shares, valued at $1.72 each, are held via Panetta Partners Limited. This transaction increases Cerrone's indirect holdings ", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-4-okyo-pharma-ltd-insider-trading-activity-a3616b34e7fa.html", "source_name": "Stock Titan", "published_at": "2026-06-11T09:09:36", "published_display": "11 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85", "summary": "OKYO Pharma Ltd.'s Chief Financial Officer, Keeren Rameshchandra Shah, was granted options for 40,000 common shares at an exercise price of $1.85 per share. These compensation-related options become exercisable on June 8, 2027, and expire on June 8, 2036. Following this grant, Sh", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-4-okyo-pharma-ltd-insider-trading-activity-653b0a575bec.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:56", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) director awarded options on 3,500 common shares", "summary": "OKYO Pharma director Bernard Denoyer was granted options for 3,500 common shares with an exercise price of $1.85 per share, expiring on June 8, 2036. This compensation-related award increases his total option holdings to 35,190 shares. The options vest 25% annually over four year", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-4-okyo-pharma-ltd-insider-trading-activity-cea2c0537eca.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:56", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO)", "summary": "This article provides an in-depth financial overview of OKYO Pharma Ltd. (NASDAQ:OKYO), detailing its current stock price of $1.68, recent performance trends, and key statistics like market capitalization and EPS. It also includes technical analysis ratings, analyst forecasts wit", "url": "https://www.chartmill.com/stock/quote/OKYO/profile", "source_name": "ChartMill", "published_at": "2026-05-29T16:10:43", "published_display": "29 May 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma expands scientific advisory board with cornea expert - ICYMI", "summary": "OKYO Pharma recently appointed Dr. Marta Sacchetti to its scientific advisory board to strengthen its clinical programs for neuropathic corneal pain. The company's lead candidate, Urcosimod, is a non-opioid eye drop designed to alleviate pain and inflammation for this debilitatin", "url": "https://ca.finance.yahoo.com/news/okyo-pharma-expands-scientific-advisory-120000504.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-05-24T00:09:52", "published_display": "24 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Ltd (OKYO) CFO details equity and option positions", "summary": "OKYO Pharma Ltd's CFO, Keeren Rameshchandra Shah, has disclosed his existing equity and option holdings in the company through a Form 3 SEC filing. He directly holds 16,667 shares of common stock. The filing also details numerous option awards, including grants for 31,250 shares ", "url": "https://www.stocktitan.net/sec-filings/OKYO/form-3-okyo-pharma-ltd-initial-statement-of-beneficial-ownership-2c9960e0d26d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:09:27", "published_display": "22 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Okyo Pharma Appoints Marta Sacchetti, MD, Ph.D., to Scientific Advisory Board", "summary": "Okyo Pharma Limited (Nasdaq: OKYO) has expanded its scientific advisory board by appointing Marta Sacchetti, MD, PhD, an associate professor of ophthalmology at Link University in Rome. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases and ocular surface diseases w", "url": "https://www.visionmonday.com/business/article/okyo-pharma-appoints-marta-sacchetti-md-phd-to-scientific-advisory-board/", "source_name": "VisionMonday.com", "published_at": "2026-05-20T12:15:00", "published_display": "20 May 2026 12:15", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes OKYO Pharma (OKYO) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOLVJ0SlJUelVjZTB1UXNoMTNoTG5tWklEUnBNSTFwMlB5b1lxNWtST2FMb2xFTzd1SE1weHJCODJMWkZCQlpFRFVJMWxtMUN3S2YwUW00WGhLV3JCUXFMZmNNMnlfYkpPRmotX1FtZzNEUTBveXo1MEFlSzlHUTdTWWtKRzQ5c1FTVXBaSEd5ZFd0amJqelE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment", "summary": "OKYO Pharma has appointed Dr. Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing the company's expertise in ophthalmic programs. Dr. Sacchetti brings extensive experience in neuro-inflammatory corneal diseases, aligning with OKYO Pharma's focus on unmet needs i", "url": "https://www.proactiveinvestors.ca/companies/news/1092546/okyo-pharma-strengthens-scientific-advisory-board-with-marta-sacchetti-appointment.html?region=ca", "source_name": "Proactive financial news", "published_at": "2026-05-19T14:40:24", "published_display": "19 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma appoints Marta Sacchetti to advisory board By Investing.com", "summary": "OKYO Pharma has appointed Marta Sacchetti, MD, PhD, to its Scientific Advisory Board. Dr. Sacchetti is an Associate Professor of Ophthalmology at Link University in Rome and previously served as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Domp\u00e9 Farmaceut", "url": "https://ca.investing.com/news/stock-market-news/okyo-pharma-appoints-marta-sacchetti-to-advisory-board-93CH-4647966", "source_name": "Investing.com Canada", "published_at": "2026-05-19T11:39:34", "published_display": "19 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD", "summary": "OKYO Pharma Limited has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti, an international expert in ocular inflammatory and degenerative diseases. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases will be crucial for the company's", "url": "https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/okyo-expands-scientific-advisory-board-with-the-appointment-of-international-expert-marta-sacchetti-md-phd/2347017/amp", "source_name": "The Manila Times", "published_at": "2026-05-19T10:39:34", "published_display": "19 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma (OKYO) deepens NCP program with new advisory board expert", "summary": "OKYO Pharma announced the expansion of its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti, an expert in corneal and ocular surface diseases, to bolster its neuropathic corneal pain (NCP) program. The company is developing Urcosimod, an investigational drug ", "url": "https://www.stocktitan.net/sec-filings/OKYO/6-k-okyo-pharma-ltd-current-report-foreign-issuer-e9636def7009.html", "source_name": "Stock Titan", "published_at": "2026-05-19T10:39:34", "published_display": "19 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board", "summary": "OKYO Pharma Ltd (NASDAQ:OKYO) has appointed Dr. Marta Sacchetti, an ophthalmology specialist, to its Scientific Advisory Board. This addition aims to strengthen the company's clinical programs in neuropathic corneal pain and inflammatory eye diseases, leveraging Dr. Sacchetti's e", "url": "https://www.proactiveinvestors.com/companies/news/1092537/okyo-pharma-adds-ophthalmology-specialist-marta-sacchetti-to-scientific-advisory-board-1092537.html", "source_name": "Proactive financial news", "published_at": "2026-05-19T09:58:00", "published_display": "19 May 2026 09:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May", "summary": "OKYO Pharma Limited's CEO, Robert J. Dempsey, and CSO, Raj Patil, PhD, will present at upcoming scientific conferences in May. Dempsey will speak at Eyecelerator on addressing unmet needs in corneal and anterior segment diseases, while Patil will present at the ARVO Annual Meetin", "url": "https://sg.finance.yahoo.com/news/okyo-ceo-cso-present-leadership-110000120.html", "source_name": "Market source", "published_at": "2026-04-30T03:09:34", "published_display": "30 Apr 2026 03:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April", "summary": "OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) experienced a significant 31.9% increase in short interest in April, reaching 272,194 shares. This represents approximately 1.1% of the company's shares sold short, with a days-to-cover ratio of 2.5 days. The company's stock is curr", "url": "https://www.marketbeat.com/instant-alerts/okyo-pharma-limited-sponsored-adr-nasdaqokyo-short-interest-up-319-in-april-2026-04-29/", "source_name": "MarketBeat", "published_at": "2026-04-30T02:10:05", "published_display": "30 Apr 2026 02:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Pharma taps Leerink to raise cash for eye pain treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdXdEbWtMb2dMUXJKbUJoMUZKTllGNl9IRC1INWs3VTluM1VsbmdteGtaYzNCdksxeTgtM0VwNXJtTlVmaTZ2amV6bGgwQ1BJRklIaHVLTy1WdWw2VnlBMC11ZjBaTEliRlIxRjY2aW1YYnlCUGNPc3VMeHpMNmVYRlRuWnk2WHZVMC1LYnJYM0xzeVF1WGZtWFZvR09ZWk44dHNKc1JkUHQySXRWa1pfeFpBSjRZVnBPQ3VLcQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Doctor behind $1B rare-disease eye drug joins OKYO Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTVlpYjZkUkVFZkFsUDBxc19Jc1ZkZ3plcmVCRjNfRmczT09YNFpMd0xzZUpGdEg0TVhjYm1vXy1RXzlydkhWOFBtZkJGNXdvdXRyUHlnU1EyUkw3Z1lUOTRCaGY1MEJhVDZlWnJwVnRWLTNEVHdGNDBYR2pWZERGUjZXQkNXa2QwN3J5WGc2X245N3NScUIyWENfb05jYmYxdU9oTzZaM1Rua2xna1d3UGtuLW9rQ2dmWm9iM1pHOW4?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKYO Stock Price and Chart \u2014 NASDAQ:OKYO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBCNUVkcEhQVThLS0padUZUenhWbVhtMjlzcExjR1lmUVVYX2c0WnVmQ0xhT1BqX2FTUnM0Sk44Mkt0RndyZjZnWEdWck5oaG0wSmFUeEV0U084R094?oc=5", "source_name": "TradingView", "published_at": "2025-03-31T07:00:00+00:00", "published_display": "31 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 82, "total_relevant": 46, "sentiment_summary": {"positive": 22, "negative": 3, "neutral": 21, "score": 59, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.69, "latest_week": "2026-07-10", "one_week_move": 7.6, "four_week_move": 11.2, "twelve_week_move": 1.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.46813, "market_dynamics_buy_signal": false, "relative_strength": -29.374945, "fair_value_gap": 1.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.3832, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.6% over one week, +11.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 71, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 7}, {"label": "Proactive", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "The Globe and Mail", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Proactive financial news", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.6% over one week, +11.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Cuts Target Price to $5"}], "updated_at": "2026-07-16T05:42:09.009181+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}